Tenet Healthcare Corporation Revenue & Financials

Tenet Healthcare Corporation closed fiscal year 2024 with total consolidated revenues of $20.33 billion, representing a 3.2% increase from the $19.70 billion reported in FY2023, driven primarily by favorable commercial reimbursement rate increases, stabilized inpatient patient volumes, and the continued EBITDA accretion from its United Surgical Partners International (USPI) ambulatory surgery center joint ventures. The company's financial performance in FY2024 was characterized by a relentless focus on margin expansion and balance sheet deleveraging, resulting in Adjusted EBITDA of $2.74 billion, an Adjusted EBITDA margin of 13.5%, and net income attributable to Tenet Healthcare Corporation of $1.12 billion, a massive improvement from the net losses and margin compression experienced during the peak of the pandemic-era labor crisis in FY2021 and FY2022. The Hospital Operations segment generated $17.3 billion in revenue, with same-hospital acute care admissions increasing by 1.8% year-over-year and emergency room visits stabilizing at pre-pandemic baseline levels, while the critical metric of adjusted admissions per equivalent licensed bed demonstrated improved operational efficiency and capacity utilization across the 61-hospital network. The USPI segment was the standout financial performer, generating $2.0 billion in revenue and contributing $550 million in Adjusted EBITDA, with same-facility revenue growth of 6.5% driven by strong procedural volume growth in orthopedics, gastroenterology, and ophthalmology, and the successful integration of over 20 new de novo and acquired ambulatory surgery centers into the joint venture network. Conifer Health Solutions generated $1.0 billion in revenue, with third-party revenue growing by 8% as the company successfully signed new multi-year enterprise contracts with external health systems, while simultaneously improving its internal days in accounts receivable to 48 days, well below the industry average of 54 days, thereby accelerating cash flow and reducing the need for external working capital financing. The company's capital allocation strategy in FY2024 was strictly disciplined, prioritizing debt reduction above all other uses of capital; Tenet utilized its robust free cash flow of $1.8 billion to repay $1.5 billion in long-term debt, including the early redemption of several high-coupon senior notes, which reduced the company's total long-term debt to $8.2 billion and lowered its annualized interest expense by $65 million. This aggressive deleveraging improved Tenet's leverage ratio (Net Debt to Adjusted EBITDA) to 2.1x, positioning the company for a potential credit rating upgrade to investment-grade status in FY2025, which would further reduce its borrowing costs and expand its access to the commercial paper market. Operating cash flow for FY2024 was $2.4 billion, providing ample liquidity to fund the company's $400 million in annual capital expenditures, which were strategically directed toward high-return outpatient projects, IT infrastructure upgrades for Conifer, and targeted facility renovations in high-margin service lines, rather than traditional inpatient bed expansion. The financial narrative of Tenet Healthcare in FY2024 is one of a company that has successfully navigated the most severe labor and inflationary shock in the history of the American hospital industry, emerging with a streamlined, optimized operational footprint, a highly profitable and rapidly growing outpatient platform, and a balance sheet that is finally providing the financial flexibility required to compete aggressively in the next phase of healthcare industry consolidation.